Science & Technology
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer
Department of Health and Human Services — National Institutes of Health
Opportunity #: 4R44CA285233-02
Award Ceiling
$2.2M
Award Floor
$2.2M
Close Date
Aug 31, 2026
169 days leftTotal Funding
$2.2M
Expected Awards
1
Posted Date
Sep 1, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-4R44CA285233-02
Description
SBIR Phase Phase II award: "PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer" awarded to PDX PHARMACEUTICALS, INC. in PORTLAND, Oregon. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $2,202,500. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.